Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Psoriasis vulgaris is a chronic recurrent genetically determined dermatosis with multifactorial nature, characterized by hyperproliferation and impaired differentiation of keratinocytes, inflammatory reaction in the dermis, immune disorders and lesions of the skin, nails, joints and other organs. The article presents a review of the current literature data on the etiology and pathogenesis of psoriasis and its association with various comorbidities, psycho-emotional and socio-economic status. Among the most common comorbidities, depending on the severity of psoriasis, there are cardiovascular diseases, diabetes mellitus, metabolic syndrome. In addition, psoriasis vulgaris often affects people of working age, leading to psychological and social desadaptation, decrease of work capacity, depressive disorder.

Full Text

Restricted Access

About the authors

O. Yu Olisova

I. M. Sechenov First Moscow State Medical University

Moscow, 119991, Russian Federation

Lusine G. Garanyan

I. M. Sechenov First Moscow State Medical University

Email: lusine90@list.ru
Moscow, 119991, Russian Federation
Department of Dermatology and Venereology, I. M. Sechenov First Moscow State Medical University, Moscow, 119991, Russian Federation


  1. Олисова О.Ю. Псориаз: эпидемиология, патогенез, клиника, лечение. Consilium medicum. Дерматология. 2010; 4: 3-8
  2. Naldi L., Svensson A., Diepgen T., Elsner P., Grob J.J., Coenraads P.J., et al.; European Dermato-Epidemiology Network. Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J. Invest. Dermatol. 2003; 120(5): 738-41.
  3. Parisi R., Symmons D.P., Griffiths C.E., Ashcroft D.M. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J. Invest. Dermatol. 2013; 133(2): 377-85.
  4. Gelfand J.M., Troxel A.B., Lewis J.D. The risk of mortality in patients with psoriasis. Results from a populationbased study. Arch. Dermatol. 2007; 143(12): 1493-9.
  5. Знаменская Л.Ф., Мелехина Л.Е., Богданова Е.В., Минеева А.А. Заболеваемость и распространенность псориаза в Российской Федерации. Вестник дерматологии и венерологии. 2012; 5: 20-9
  6. Azfar R.S., Gelfand J.M. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr. Opin. Rheumatol. 2008; 20(4): 416-22.
  7. Gustafson B., Hammarstedt A., Andersson C.X., Smith U. Inflamed adipose tissue a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2007; 27(11): 2276-83.
  8. Gladman D.D., Farewell W.T., Wong K., Husted J. Mortality stadies in psoriatic arthritis. Arthr. Reum. 1998; 41(6): 1103-10.
  9. Katsambas A., Lotti T., Dessinioti, C., D’Erme, A.M. European handbook of dermatological treatments. Springer; 2015.
  10. Meffert J., James W.D. Psoriasis. Available at: http://emedicine.medscape.com/article/1943419-overview#a0101 Access 12.06.16.
  11. Болевич С.Б., Уразалина А.А. Псориаз: современный взгляд на этиопатогенез. Вестник Российской военно-медицинской академии. 2013; (2): 202-6
  12. Hunter H.J., Griffiths C.E., Kleyn C.E. Does psychosocial stress play a role in the exacerbation of psoriasis? Br. J. Dermatol. 2013; 169(5): 965-74.
  13. Garg A., Chren M.M., Sands L.P., Matsui M.S., Marenus K.D., Feingold K.R., Elias P.M. Psychological stress perturbs epidermal permeability barrier homeostasis: implications for the pathogenesis of stress-associated skin disorders. Arch. Dermatol. 2001; 137(1): 53-9.
  14. Кочергин Н.Г., Смирнова Л.М. Последние тренды в лечении псориаза. Лечащий врач. 2011; 5: 42-4
  15. James W.D., Berger T., Elston D. Andrews’ diseases of the skin: clinical dermatology. Elsevier; 2015.
  16. Menon K., Van Voorhees A.S., Bebo B.F., Gladman D.D., Hsu S., Kalb R.E. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J. Am. Acad. Dermatol. 2010; 62(2): 291-9.
  17. Uyemura K., Yamamura M., Fivenson D.F., Modlin R.L., Nickoloff B.J. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J. Invest. Dermatol. 1993; 101(5): 701-5.
  18. Кубанова А.А., Кубанов А.А., Николас Дж.Ф., Пьюиг Л., Принц Дж., Катунина О.Р., Знаменская Л.Ф. Иммунные механизмы псориаза. Новые стратегии биологической терапии. Вестник дерматологии и венерологии. 2010; 1: 35-47
  19. Di Cesare A., Di Meglio P., Nestle F. O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J. Invest. Dermatol. 2009; 129(6): 1339-50.
  20. Zheng Y., Danilenko D.M., Valdez P., Kasman I., Eastham-Anderson J., Wu J., Ouyang W. Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007; 445(7128): 648-51.
  21. Lowes M.A., Kikuchi T., Fuentes-Duculan J., Cardinale I., Zaba L.C., Haider A.S., Krueger J.G. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Invest. Dermatol. 2008; 128(5): 1207-11.
  22. Coates L., Savage L., Emery P. Pathogenesis of psoriasis and psoriatic arthritis. Handbook of Psoriasis and Psoriatic Arthritis. Springer; 2016: 7-16.
  23. Кочергин Н.Г., Потекаев Н.Н., Смирнова Л.М., Серов Д.Н., Олисова О.Ю., Бабушкин А.М. Наш первый опыт применения адалимумаба при псориазе. Российский журнал кожных и венерических болезней. 2012; 15(5): 37-41
  24. Kollipara R., Downing C., Gordon R., Tyring S. Interleukin-23 in the pathogenesis and treatment of psoriasis. Skin Therapy Lett. 2015; 20(2): 1-4.
  25. Keaney T.C., Kirsner R.S. New insights into the mechanism of narrow-band UVB therapy for psoriasis. J. Invest. Dermatol. 2010; 130(11): 2534.
  26. Martin D.A., Towne J.E., Kricorian G., Klekotka P., Gudjonsson J.E., Krueger J.G., Russell C.B. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J. Invest. Dermatol. 2013; 133(1): 17-26.
  27. Hong K., Chu A., Ludviksson B.R., Berg E.L., Ehrhardt R.O. IL-12, independently of IFN-γ, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J. Immunol. 1999; 162(12): 7480-91.
  28. Chan J.R., Blumenschein W., Murphy E., Diveu C., Wiekowski M., Abbondanzo S., Gorman D.M. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J. Exp. Med. 2006; 203(12): 2577-87.
  29. Capon F., Di Meglio P., Szaub J., Prescott N.J., Dunster C., Baumber L., et al. Sequence variants in the genes for the interleukin-23 receptor (IL-23R) and its ligand (IL-12B) confer protection against psoriasis. Hum. Genet. 2007; 122(2): 201-6.
  30. Cargill M., Schrodi S.J., Chang M., Garcia V.E., Brandon R., Callis K.P., Leong D.U. A large-scale genetic association study confirms IL-12B and leads to the identification of IL-23R as psoriasis-risk genes. Am. J. Human Gen. 2007; 80(2): 273-90.
  31. Дегтярев О.В., Меснянкина О.А. Патогенетическая роль нарушений липидного профиля при псориазе. Российский журнал кожных и венерических болезней. 2015; 18(1): 30-3.
  32. Кочергин Н.Г., Смирнова Л.М., Потекаев Н.Н, Билалова У.Г. Псориаз: коморбидности и комедикации. Врач. 2009; 5: 15-20.
  33. Li K., Armstrong A.W. A review of health outcomes in patients with psoriasis. Dermatol. Clin. 2012; 30(1): 61-72.
  34. Griffiths C.E., Barker J.N. Pathogenesis and clinical features of psoriasis. Lancet. 2007; 370(9583): 263-71.
  35. Yoo H., Kim S.J., Kim Y., Lee H., Kim T.Y. Insulin-like growth factor-II regulates the 12-lipoxygenase gene expression and promotes cell proliferation in human keratinocytes via the extracellular regulatory kinase and phosphatidylinositol 3-kinase pathways. Int. J. Biochem. Cell Biol. 2007; 39(6): 1248-59.
  36. Zaina S., Nilsson J. Insulin-like growth factor II and its receptors in atherosclerosis and in conditions predisposing to atherosclerosis. Curr. Opin. Lipidol. 2003; 14(5): 483-9.
  37. Cao Y. Angiogenesis modulates adipogenesis and obesity. J. Clin. Invest. 2007; 117(9): 2362-8.
  38. Deanfield J.E., Halcox J.P., Rabelink T.J. Endothelial function and dysfunction testing and clinical relevance. Circulation. 2007; 115(10): 1285-95.
  39. Ryan C., Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol. Clin. 2015; 33(1): 41-55.
  40. Kaye J.A., Li L., Jick S.S. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br. J. Dermatol. 2008; 159(4): 895-902.
  41. Abuabara K., Azfar R.S., Shin D.B., Neimann A.L., Troxel A.B., Gelfand J.M. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK. Br. J. Dermatol. 2010; 163(3): 586-92.
  42. Eckel R.H., Grundy S.M., Zimmet P. The metabolic syndrome. Lancet. 2005; 365(9468): 1415-28.
  43. Sommer D.M., Jenisch S., Suchan M., Christophers E., Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch. Dermatol. Res. 2007; 298(7): 321-8.
  44. Langan S.M., Seminara N.M., Shin D.B., Troxel A.B., Kimmel S.E., Mehta N.N., et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J. Invest. Dermatol. 2012; 132(3): 556-62.
  45. Goldminz A.M., Buzney C.D., Kim N., Au S.C., Levine D.E., Wang A.C., et al. Prevalence of the metabolic syndrome in children with psoriatic disease. Pediatr. Dermatol. 2013; 30(6): 700-5. doi: 10.1111/pde.12218.
  46. Wu S., Li W.Q., Han J., Sun Q., Qureshi A.A. Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women. Arthritis. Rheumatol. 2014; 66(2): 304-10.
  47. Mehta N.N., Li R., Krishnamoorthy P., Yu Y., Farver W., Rodrigues A., et al. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis. 2012; 224(1): 218-21.
  48. Holzer M., Wolf P., Inzinger M., Trieb M., Curcic S., Pasterk L., et al. Anti-psoriatic therapy recovers high-density lipoprotein composition and function. J. Invest. Dermatol. 2014; 134(3): 635-42.
  49. Armstrong A.W., Harskamp C.T., Armstrong E.J. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013; 149(1): 84-91.
  50. Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B., Gelfand J.M. Prevalence of cardiovascular risk factors in patients with psoriasis. J. Am. Acad. Dermatol. 2006; 55(5): 829-35.
  51. Setty A. R., Curhan G., Choi H.K. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses’ Health Study II. Arch. Intern. Med. 2007; 167(15): 1670-5.
  52. Mallbris L., Granath F., Hamsten A., Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J. Am. Acad. Dermatol. 2006; 54(4): 614-21.
  53. Herron M.D., Hinckley M., Hoffman M.S., Papenfuss J., Hansen C.B., Callis K.P., Krueger G.G. Impact of obesity and smoking on psoriasis presentation and management. Arch. Dermatol. 2005; 141(12): 1527-34.
  54. Paller A.S., Mercy K., Kwasny M.J., Choon S.E., Cordoro K.M., Girolomoni G., et al. Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatol. 2013; 149(2): 166-76.
  55. Розумбаева Л.П., Козлова И.В., Бакулев А.Л., Быкова А.П. Клинические и инструментальные особенности гепатобилиарной системы при псориазе. Экспериментальная и клиническая гастроэнтерология. 2014; (2): 64а.
  56. Смирнова A.В., Барило A. А., Смольникова A. В. Заболевания гепатобилиарной системы как предикторы прогрессирования псориаза. Вестник Российской академии медицинских наук. 2016; 71(2): 102-8.
  57. Miele L., Vallone S., Cefalo C., La Torre G., Di Stasi C., Vecchio F. M., Pompili M. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J. Hepatol. 2009; 51(4): 778-86.
  58. Lonardo A., Loria P., Carulli N. Concurrent non-alcoholic steatohepatitis and psoriasis. Report of three cases from the POLI. ST. E.N.A. study. Dig. Liver Dis. 2001; 33(1): 86-7.
  59. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatology. 1986; 172(6): 298-304.
  60. Gelfand J.M., Berlin J., Van Voorhees A., Margolis D.J. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch. Dermatol. 2003; 139(11): 1425-9.
  61. Gottlieb A.B., Chao C., Dann F. Psoriasis comorbidities. J. Dermatol. Treat. 2008; 19(1): 5-21.
  62. Olsen J.H., Moller H., Frentz G. Malignant tumors in patients with psoriasis. J. Am. Acad. Dermatol. 1992; 27(5): 716-22.
  63. Boffetta P., Gridley G., Lindelof B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J. Invest. Dermatol. 2001; 117(6): 1531-7.
  64. Pouplard C., Brenaut E., Horreau C., Barnetche T., Misery L., Richard M.A. Risk of cancer in psoriasis: a systematic review and metaanalysis of epidemiological studies. J. Eur. Acad. Dermatol. Venereol. 2013; 27(3): 36-46.
  65. Paul C.F., Ho V.C., McGeown C., Christophers E., Schmidtmann B., Guillaume J.C., Dubertret L. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J. Invest. Dermatol. 2003; 120(2): 211-6.
  66. Donigan J.M., Snowden C., Carter J.B., Kimball A.B. The temporal association between cutaneous T-cell lymphoma and psoriasis: implications for common biologic processes. J. Eur. Acad. Dermatol. Venereol. 2016; 30(10):e31-e32. doi: 10.1111/jdv.13281
  67. Kimball A.B., Jacobson C., Weiss S., Vreeland M.G., Wu Y. The psychosocial burden of psoriasis. Am. J. Clin. Dermatol. 2005; 6(6): 383-92.
  68. Krueger G., Koo J., Lebwohl M., Menter A., Stern R.S., Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol. 2001; 137(3): 280-4.
  69. Пирузян Э.С., Никольская Т.А., Абдеев Р.М., Брускин С.А. Компоненты транскрипционного фактора AP-1 как гены-кандидаты на участие в развитии псориатического процесса. Молекулярная биология. 2007; 41(6): 1069-80.
  70. Маркушева Л.И., Самсонов В.А., Саруханова А.Г., Саватеева М.В. Оценка продукции различных цитокинов у больных псориазом. Вестник дерматологии и венерологии. 2004; 4: 4-6.
  71. Moon H.S., Mizara A., McBride S.R. Psoriasis and psycho-dermatology. Dermatol. Ther. (Heidelb). 2013; 3(2): 117-30.
  72. Rashid M. H. A., Mullick M. S., Jaigirdar M. Q. H., Ali R., Nirola D. K., Salam M. A., Ahsan M. S. Psychiatric Morbidity in Psoriasis and Vitiligo in Two Tertiary Hospitals in Bangladesh. Bangabandhu Sheikh Mujib Med. University J. 2011; 4(2): 88-93. указать сайт,где «в один клик» можно прочитать эту работу
  73. Schiepers O.J., Wichers M.C., Maes M. Cytokines and major depression. Prog. NeuroPsychopharmacol. Biol. Psychiatry. 2005; 29(2): 201-7.
  74. Ginsburg I.H., Link B.G. Feelings of stigmatization in patients with psoriasis. J. Am. Acad. Dermatol. 1989; 20(1): 53-63.
  75. Eghlileb A.M., Davies E.E., Finlay A.Y. Psoriasis has a major secondary impact on the lives of family members and partners. Br. J. Dermatol. 2007; 156(6): 1245-50.
  76. Poot F., Antoine E., Gravellier M., Hirtt J., Alfani S., Forchetti G., et al. A case-control study on family dysfunction in patients with alopecia areata, psoriasis and atopic dermatitis. Acta Derm. Venereol. 2011; 91(4): 415-21.
  77. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006; 367(9504): 29-35.
  78. D’Erme A.M., Zanieri F., Campolmi E., Santosuosso U., Betti S., Agnoletti A.F., et al. Therapeutic implications of adding the psychotropic drug escitalopram in the treatment of patients suffering from moderate-severe psoriasis and psychiatric comorbidity: a retrospective study. J. Eur. Acad. Dermatol. Venereol. 2014; 28(2): 246-9.
  79. Tan Pei Lin L., Kwek S.K. Onset of psoriasis during therapy with fluoxetine. Gen. Hosp. Psychiatry. 2010; 32(4): 446.e9-446.e10.
  80. Tamer E., Gur G., Polat M., Alli N. Flare-up of pustular psoriasis with fluoxetine: Possibility of a serotoninergic influence? J. Dermatol. Treat. 2009; 20(3): 137-40.
  81. Cox N.H., Gordon P.M., Dodd H. Generalized pustular and erythrodermic psoriasis associated with bupropion treatment. Br. J. Dermatol. 2002; 146(6): 1061-3.
  82. Basavaraj K.H., Ashok N.M., Rashmi R., Praveen T.K. The role of drugs in the induction and/or exacerbation of psoriasis. Intern.J. Dermatol. 2010; 49(12): 1351-61.
  83. Ayala F., Sampogna F., Romano G.V., Merolla R., Guida G., Gualberti G. The impact of psoriasis on work-related problems: a multicenter cross-sectional survey. J. Eur. Acad. Dermatol. Venereol. 2014; 28(12): 1623-32.
  84. Brezinski E.A., Dhillon J.S., Armstrong A.W. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015; 51(6): 651-8.
  85. Horn E.J., Fox K.M., Patel V., Chiou C.F., Dann F., Lebwohl M. Association of patient-reported psoriasis severity with income and employment. J. Am. Acad. Dermatol. 2007; 57(6): 963-71.
  86. Reich K., Schenkel B., Zhao N., Szapary P., Augustin M., Bourcier M., et al. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. J. Dermatolog. Treat. 2011; 22(6): 337-47.
  87. Kimball A.B., Yu A.P., Signorovitch J., Xie J., Tsaneva M., Gupta S.R., et al. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. J. Am. Acad. Dermatol. 2012; 66(2): e67-76.
  88. Hawro T., Maurer M., Hawro M., Kaszuba A., Cierpialkowska L., Krolikowska M., Zalewska A. In psoriasis, levels of hope and quality of life are linked. Arch. Dermatol. Res. 2014; 306(7): 661-6. doi: 10.1007/s00403-014-1455-9.



Abstract - 49

PDF (Russian) - 0


Article Metrics

Metrics Loading ...



Copyright (c) 2017 Olisova O.Y., Garanyan L.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies